Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease

ClinicalTrials.gov ID: NCT00102921

Public ClinicalTrials.gov record NCT00102921. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research study is to investigate the effects of an investigational medication, called CCX282-B, on safety and on the some of the symptoms of Crohn's Disease in patients who are experiencing an active flare-up of moderate to severe Crohn's Disease.

Study identification

NCT ID
NCT00102921
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
70 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2004 (Type not available)
Primary completion
Not listed
Completion
Dec 2005 (Type not available)
Last update posted
Mar 6, 2025

2004 – 2005

United States locations

U.S. sites
14
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
Cedars-Sinai Medical Center Los Angeles California 90048 —
Rocky Mountain Clincal Research Golden Colorado 80104 —
Arapahoe Gastroenterology Littleton Colorado 80120 —
Atlanta Gastroenterology Associates Atlanta Georgia 30342 —
University of Chicago Chicago Illinois 60637 —
Mayo Clinic Rochester Rochester Minnesota — —
Comprehensive Clinical Research Berlin New Jersey 08009 —
Long Island Clinical Research Associates, LLP Great Neck New York 11021 —
Wake Forest Research Raleigh North Carolina 27612 —
University Hospitals of Cleveland, Div of Gastroenterology Cleveland Ohio 44106-5066 —
Digestive Disease Clinic Jackson Tennessee 38305 —
Nashville Medical Research Institute Nashville Tennessee 37205 —
Center for Colon Rectal Disease Salt Lake City Utah 84124 —
University of Virginia Health System, Digestive Health Center of Excellence Charlottesville Virginia 22908 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00102921, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 6, 2025 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00102921 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →